TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) Starts Presentation at 30th Annual ROTH Conference
TRACON (NASDAQ: TCON) develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. For more information, visit the company’s website at www.traconpharma.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company…







